Literature DB >> 14706213

Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?

Shauna Kirk1, Joseph A Frank, Stephen Karlik.   

Abstract

Characteristic pathological features of multiple sclerosis (MS) include inflammation, demyelination and axonal and oligodendrocyte loss. In addition, lesions can also have a significant vascular component. In this review, morphological, biochemical and radiological evidence is presented suggesting angiogenesis as a potential focus for investigation in MS. We hypothesize that angiogenesis plays a significant role in the MS lesion, perpetuating disease progression. Thus, treatment strategies that inhibit angiogenesis may decrease clinical and pathological signs of disease. Several approaches for testing this hypothesis are outlined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706213     DOI: 10.1016/j.jns.2003.10.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

1.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

2.  Extensive vascular remodeling in the spinal cord of pre-symptomatic experimental autoimmune encephalomyelitis mice; increased vessel expression of fibronectin and the α5β1 integrin.

Authors:  Amin Boroujerdi; Jennifer V Welser-Alves; Richard Milner
Journal:  Exp Neurol       Date:  2013-09-20       Impact factor: 5.330

3.  Visual Function and Disability Are Associated with Increased Retinal Volumetric Vessel Density in Patients with Multiple Sclerosis.

Authors:  Hong Jiang; Giovana Rosa Gameiro; Yi Liu; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovanni Gregori; Silvia Delgado; Jianhua Wang
Journal:  Am J Ophthalmol       Date:  2020-01-08       Impact factor: 5.258

4.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

5.  Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.

Authors:  Candice Chapouly; Azeb Tadesse Argaw; Sam Horng; Kamilah Castro; Jingya Zhang; Linnea Asp; Hannah Loo; Benjamin M Laitman; John N Mariani; Rebecca Straus Farber; Elena Zaslavsky; German Nudelman; Cedric S Raine; Gareth R John
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

Review 6.  Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Authors:  Frank Alexis; Eric Pridgen; Linda K Molnar; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2008-08-04       Impact factor: 4.939

7.  Angiogenesis induced by CNS inflammation promotes neuronal remodeling through vessel-derived prostacyclin.

Authors:  Rieko Muramatsu; Chisato Takahashi; Shuzo Miyake; Harutoshi Fujimura; Hideki Mochizuki; Toshihide Yamashita
Journal:  Nat Med       Date:  2012-10-07       Impact factor: 53.440

Review 8.  The blood-brain barrier in neurodegenerative disease: a rhetorical perspective.

Authors:  Paul M Carvey; Bill Hendey; Angela J Monahan
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

9.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

10.  Longitudinal Study of Retinal Structure, Vascular, and Neuronal Function in Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Follow-Up.

Authors:  Qi Chen; Hong Jiang; Silvia Delgado; Jeffrey Hernandez; Diego Eduardo Alba; Giovanni Gregori; Kottil W Rammohan; Vittorio Porciatti; Jianhua Wang
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.